Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
- DOI
- 10.1186/s13046-018-0999-5
- Published
- 2019-01-11
- Container
- Journal of Experimental & Clinical Cancer Research
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s13046-018-0999-5,
title = {Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer},
author = {Elaine Reguera-Nuñez and Ping Xu and Annabelle Chow and Shan Man and Frank Hilberg and Robert S. Kerbel},
year = {2019},
journal = {Journal of Experimental \& Clinical Cancer Research},
doi = {10.1186/s13046-018-0999-5},
url = {https://doi.org/10.1186/s13046-018-0999-5}
}RIS
TY - JOUR TI - Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer AU - Elaine Reguera-Nuñez AU - Ping Xu AU - Annabelle Chow AU - Shan Man AU - Frank Hilberg AU - Robert S. Kerbel PY - 2019 JO - Journal of Experimental & Clinical Cancer Research DO - 10.1186/s13046-018-0999-5 UR - https://doi.org/10.1186/s13046-018-0999-5 ER -
APA
Reguera-Nuñez, E., Xu, P., Chow, A., Man, S., Hilberg, F., & Kerbel, R. S. (2019). Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-018-0999-5
Source records
- crossref · retrieved 2026-09-27T07:51:05.132Z